ORIGINAL ARTICLE
Pregnancy outcome in women who survived genital or
extragenital cancer
Anis Cerovac¹,², Dženita Ljuca³, Gordana Bogdanović³, Gordana Grgić³, Haris Zukić³
¹Department of Gynaecology and Obstetrics, General Hospital Tešanj, Tešanj, ²Department of Anatomy, School of Medicine, University
of Tuzla, Tuzla, ³Clinic for Gynaecology and Obstetrics, University Clinical Centre Tuzla, Tuzla; Bosnia and Herzegovina
ABSTRACT
Aim To investigate clinical and obstetrical characteristics, an
outcome and a prognosis for pregnant women with diagnosed and
treated genital or extragenital cancer and their newborns.
Methods This retrospective cohort study included pregnant and
childbearing women with a history of cancer diagnosed before pregnancy during the period between 1 January 2014 and 31
December 2018. Data related to the course of pregnancy and
childbirth were collected from medical records (mothers‘ disease
history and partogram). The analysis covered clinical and histopathological characteristics of cancers, type of the treatment (surgery,
chemotherapy, radiotherapy), demographic data, obstetric characteristics, comorbidities of women, and outcome of the newborns.
Corresponding author:
Anis Cerovac
General Hospital Tešanj
Braće Pobrić 17, 74260 Tešanj,
Bosnia and Herzegovina
Phone: +387 32 650 662;
Fax: +387 32 650 605;
E-mail: cerovac.anis@gmail.com
ORCID ID: https://orcid.org/0000-00027209-382X
Results The study recorded 18 414 deliveries, of which 30 (0.16%)
were pregnancies in women who had been diagnosed and treated
earlier for genital or extragenital cancer. The average age of the
women at the time of delivery was 29.43±5.97 years. There were
six (20%) women with genital and 24 (80%) with extragenital cancer. The most frequent extra genital cancer was Hodgkin lymphoma, in eight (26.6%) cases; ovarian cancer was the most frequent
genital cancer, in four (13.3%) cases. The average time span from
the cancer diagnosis and start of the treatment to the delivery was
59.2±44.4 months (5 years) (range 12 months - 15 years). Two
(6.6%) women died.
Conclusion Our data demonstrate a favourable obstetric and neonatal outcome for women who have survived cancer.
Original submission:
Key words: fertility, malignancy, obstetric outcome, pregnancy
06 December 2019;
Revised submission:
21 January 2020;
Accepted:
17 February 2019
doi: 10.17392/1109-20
Med Glas (Zenica) 2020; 17(2): 457-464
457
Medicinski Glasnik, Volume 17, Number 2, August 2020
INTRODUCTION
A delay of childbearing to the later reproductive age
increases the number of women who had a cancer
cured or survived a cancer (1-3). Recent advances
in oncologic diagnostic methods and treatments,
and better access to fertility sparing and infertility
treatment imply that both pregnancy and childbirth are now real options for women with history
of cancer (1,2). The most common types of cancer
in women of reproductive age are breast, genital,
hematologic, thyroid, and skin (melanoma) (3,4).
Fertility and pregnancy rates have decreased in
women with history of cancer (cancer survivors, e.
g. five years after the cancer treatment; completed
initial cancer treatment and no apparent evidence of
active disease), especially in those with leukaemia
and breast cancer (3% and 8%, respectively) (3,5).
However, these rates do not significantly differ in
malignant melanoma, thyroid cancer, and Hodgkin
lymphoma survivors (29 %, 33 % and 32%, respectively) (6). Genital cancers (including breast,
ovaries, uterine tubes and uterus) are the fourth
most commonly diagnosed cancers in women of
childbearing age (15–45 years), accounting for
16% of all cancers (6). Cancer therapy comprises
chemotherapy with agents of high gonadotoxicity;
radiotherapy treatment of the ovaries, vagina, or
uterus can have detrimental effects on the patient’s
ability to achieve reproductive function and carry
pregnancy to term (2,6). Fertility-sparing surgeries
are aimed at preserving woman’s fertility, providing options for girls and women of reproductive
age with genital cancer. The women with low stage/
grade/borderline genital carcinoma are eligible for
fertility-sparing surgical techniques (6); the fertility
sparing treatment in these women has not negatively affected overall women survival rate or quality of life, with good reproductive and pregnancy
outcomes (6). Pregnancies of women after breast
cancer do not carry a worsened prognosis, but some
studies suggest an increased risk of miscarriage,
preterm birth, low birth weight, increased Caesarean delivery rate and antepartum and postpartum
haemorrhage (3). Haematological cancers account for 17% of all cancers diagnosed in girls and
women of reproductive age (7). Thyroid cancer is
the most common endocrine cancer (8). Because
of half of the patients are in the reproductive age,
effects of different treatments, such as radioactive
iodine (RAI), on future gonadal and reproductive
458
health are an important issue (8). Melanoma is the
sixth most commonly diagnosed cancer in women;
the diagnosis of melanoma is established prior to
their first pregnancy in many women. The available
evidence does not show an adverse effect of pregnancy on disease-free and overall survival, progression and/or mortality in melanoma patients (3).
The data about complications related to pregnancy
and neonatal outcome of women with history of
cancer are scarce. Some studies have reported
increased risks of diverse obstetrical, perinatal,
and neonatal complications concerning these pregnancies (1,2,9,10). However, larger studies are
required with longer follow-up periods in order
to further verify reproductive outcome following
fertility-sparing techniques for women diagnosed
with genital and extragenital cancers.
Despite of the increasing importance of knowledge about the course and outcome of pregnancy
in cancer survivors in Bosnia and Herzegovina,
there have been no such studies, except for one
case report (11).
The aim of this study was to investigate clinical
and obstetric characteristics, perinatal and neonatal outcome and prognosis in pregnant women
with the history of cancer.
PATIENTS AND METHODS
Patients and study design
This retrospective cohort study included pregnant
and childbearing women with the history of cancer diagnosed before pregnancy during the period
between 1 January 2014 and 31 December 2018 at
the Clinic for Gynaecology and Obstetrics, University Clinical Centre Tuzla. Inclusion criteria were:
pregnant women who gave birth with the established diagnosis (histopathologically confirmed) and
treatment (surgery, chemotherapy or radiotherapy)
for cancer before pregnancy. Excluding criteria
were: women without histopathologically confirmed diagnosis of cancer, pregnant women with histopathologically confirmed diagnosis but whose
pregnancy ended with miscarriage (spontaneous
or induced abortion), and women with histopathologically confirmed benign borderline tumours before and during pregnancy, and carcinoma in situ
of uterine cervix (four patients).
The survey was approved by the Ethics Committee of the University Clinical Centre of Tuzla.
Cerovac et al. Pregnancy and cancer
Methods
RESULTS
Data on the course of pregnancy and childbirth
were collected on the basis of available medical records (mother’s disease history and partograms). Oncologic data analysis covered clinical
and histopathological characteristics of cancers,
date of diagnosis, type of treatment (surgery, chemotherapy, radiotherapy), and maternal survival.
Obstetrical data included the age of women at
delivery, time from diagnosis and treatment to
delivery, parity, week of gestation at delivery,
mode of delivery, obstetric comorbidities and
complications. Neonatal data included gender,
birth weight and length, intrauterine growth restriction (IUGR), Apgar score (AS) at the first
and fifth minute, congenital malformation, admission to the neonatal intensive care unit (NICU),
stillbirths, and early neonatal death.
During the observed period 18,414 deliveries
were recorded, of which 30 (0.16%) were cases
of pregnancy in women who had been earlier diagnosed and treated for genital or extragenital cancer. There were six (20%) women with genital
and 24 (80%) with extragenital cancer.
Statistical analysis
Descriptive statistics, mean value, standard deviation (SD), and percentage were used in statistical data processing.
The average women’s age at the time of the diagnosis and treatment was 23.6±67.85 (range 3-36
years); the youngest woman had brain cancer
(17.5 years old), and the oldest one had thyroid
cancer (28.1 years old). The average women’s
age at the time of delivery was 29.43±5.97 (range 16-38 years).
Women with thyroid (32.5 years), haematological (31 years) and other (malignant melanoma,
epipharyngeal cancer, hepatic angiosarcoma,
osteosarcoma of the humerus, abdominal ganglioneuroblastoma) types of cancers (28.66 years)
were older at the time of delivery than women
with genital (27 years) and brain (23.5 years)
cancers (Table 1).
Table 1. Obstetric characteristics of 30 pregnant women according to type of cancer
Characteristics
Genital
Extra genital
Haematological Thyroid
Brain
Others* Total N(%)
Number of women (No, %)
6 (20)
10 (33.3)
6 (20)
2 (6.66)
6 (20)
30
Age at time of diagnosis and treatment (mean SD) (years)
21±8.31
25±6.1
28.1±5.03 17.5±6.3 21.83±11.4 23.66±7.85
Age at time of delivery (mean SD) (years)
27±6.72
30.7±4.2
32.5±4.5 23.5±3.5 28.6±8.3 29.43±5.97
Time span from treatment to delivery (mean SD) (years)
4.58±3.92
5.8±3.6
4.3±2.06 6.5±2.12 8.5±5.8
5
Parity (No, %)
Primiparous
5 (83.3)
6 (60)
3 (50)
2 (100) 4 (66.6) 19 (63.33)
Secundiparous
1 (16.6)
3 (30)
3 (50)
2 (33.3) 10 (33.33)
Third and multiparous
1 (10)
1 (3.33)
Weeks of gestation (mean SD)
38.13±2.02
Delivery less than 37 weeks of gestation (No, %)
1 (16.66)
1 (10)
1 (16.66)
3 (10)
Mode of delivery (No, %)
Vaginal birth
5 (50)
5 (83.3)
2 (33.3)
12 (40)
Caesarean section
6 (100)
5 (50)
1 (16.6) 2 (100) 4 (66.6)
18 (60)
Preterm rupture of membranes (No, %)
Yes
1 (16.6)
6 (60)
4 (66.6)
1 (50)
2 (33.3) 14 (46.6)
No
5 (83.3)
4 (40)
2 (33.3)
1 (50)
4 (66.6) 16 (53.3)
Obstetrics comorbidities (No, %)
Miscarriages in reproductive anamnesis
1 (16.6)
2 (20)
1 (16.6)
4 (13.3)
Infertility/Assisted reproductive technology
1 (16.6)
1 (16.6)
2 (6.6)
Genital infection (colpitis and pelveoperitonitis)
2 (20)
3 (50)
1 (16.6) 6 (17.64)
Previous Caesarean section, uterine septum resection, myomectomy
1 (16.6)
2 (20)
1 (16.6)
1 (16.6) 4 ( 13.3)
Gestational hypertension /preeclampsia
1 (16.6) 1 (33.3) 1 (16.6)
3 (8.82)
Hypothyroidism
1 (10)
6 (100)
1 (16.6) 8 (23.52)
Other maternal comorbidities†
3 (30)
1 (16.6)
4 (13.33)
Maternal mortality
1 (16.6)
1 (10)
2 (6.6)
Type of treatment of cancers (No, %)
Surgery
6 (100)
6 (100)
2 (100) 5 (83.3) 19 (63.3)
Chemotherapy
5 (83.3)
10 (100)
2 (100) 5 (83.3) 22 (73.3)
Radiotherapy
8 (80)
6 (100)
2 (33.3) 16 (53.3)
*malignant melanoma (2), epipharyngeal cancer (1), hepatic angiosarcoma (1), osteosarcoma of the humerus (1) and abdominal ganglioneuroblastoma (1). † varicose veins, earlier surgery of persistent ductus arteriosus, avascular necrosis of the femoral head, bilateral hydronephrosis
459
Medicinski Glasnik, Volume 17, Number 2, August 2020
The most frequent were primiparous women,
in all type of cancers; one woman had twins.
The average weeks of gestation was 38.13±2.02
weeks (range 29- 40). The overall prevalence
of deliveries with less than 37 weeks gestation
was 10%. Caesarean section was a more frequent mode of delivery (60%); in genital and brain
cancers it was 100%, and the lowest in women
with thyroid cancer, 16.6%.
Preterm rupture of membranes was found in 14
(46.6%) pregnancies; most frequently in women
with haematological and thyroid cancers, 60%
and 66.6%, respectively. Miscarriages with less
than 10 weeks of gestation in reproductive anamnesis were found in 13.3% women, most frequently in haematological cancers, 20% (Table 1).
Infertility and assisted reproductive technology
was found in two (6.6%) women. Genital infection (colpitis and pelveoperitonitis) was found
in six (17.64%) women, most frequently in women with thyroid and haematological cancers
(50% and 20%). Gestational hypertension/preeclampsia was found in three (8.8%) women with
thyroid (16.6%), brain (33.3%) and other cancers
(16.6%). Hypothyreoidism was found in eight
(23.52%) women, mostly in women with thyroid
cancers (100%).
The most frequent were female newborns, in all
type of cancers. The average birth weight was
3202±557.36 (range 1250- 4070 grams). The
highest birth weight was found in women with
thyroid cancer (3471). Average birth length was
52.76±3.4 (range 40-57 centimetres) (Table 2).
The prevalence of intrauterine growth restriction was 13.3%. The average Apgar score was
8.01±1.78 (range 2- 9) in the first minute, and
8.63±0.76 (range 6-9) in the fifth minute. Imminent fetal asphyxia (Apgar score ˃7) was found
in 13.3% newborns, and incipient (Apgar score
˂7) in 16.6% newborns; 16.6% newborns were
admitted to neonatal intensive care unit. No
stillbirths and congenital malformations were
recorded (Table 2).
The most frequently encountered cancer types
were haematological, in ten (33.3%), genital,
in six (20%), and thyroid cancer, in six (20 %)
women. The most frequent was Hodgkin lymphoma, in eight (26.6%) women. Among genital cancers ovarian cancer was represented in
four (13.3%) and breast cancer in two (6.6%)
women. Among extra genital cancers, haematological (Hodgkin lymphoma, acute myeloid
leukaemia, and multiple myeloma), thyroid
cancer, brain cancers (cerebellar and lateral
ventricle cancer), and others (malignant melanoma, epipharyngeal cancer, hepatic angiosarcoma, osteosarcoma of the humerus, abdominal
ganglioneuroblastoma) were found.
One women accidentally found out that she was
pregnant (20 weeks) during the treatment for relapses of acute myeloid leukaemia M4, which
had previously been discovered and treated.
The average time span from the diagnosis and
treatment to delivery was 59.2±44.4 months (5
years), from 12 months to 15 years, the highest in
other cancers (8.5 years), and the lowest in thyroid cancer (4.3 years). Nineteen (63.3%) women
underwent surgery, 22 (73.3%) chemotherapy
and 16 (53.3%) radiotherapy. During the follow
up period (from 1 January 2014 to 31 Decem-
Table 2. Obstetric characteristics of newborns according to type of mother cancer
Characteristics
Gender (No, %)
Male
Female
Birth weight (mean SD) (g)
Birth length (mean SD) (cm)
Intrauterine growth restriction (No, %)
Apgar score (AS) (mean SD) (min)
First min.
Fifth min.
Condition of fetus after delivery (No, %)
Imminent fetal asphyxia (AS>7)
Incipient fetal asphyxia (AS<7)
Neonatal Intensive Care Unit
*the same as in Table 1
460
Genital
Extra genital
Haematological
Thyroid
Brain
Others*
Total (No, %)
2 (33.3)
4 (66.6)
3170±409.14
52.5±1.97
1 (16.6)
7 (70)
3 (30)
3144±472.02
52.5±2.5
1 (10)
2 (33.3)
1 (50)
2 (33.3)
14 (46.6)
4 (66.6)
1 (50)
4 (66.6)
16 (53.3)
3471.6±463.48 3345±360.62 2815.71±989.3 3202±557.36
54.6±2.65
55±1.41
49.42±6.57
52.76±3.45
2 (33.3)
4 (13.3)
8.5±0.83
8.83±0.40
7.4±2.01
8.3±0.82
9±0
9±0
9±0
9±0
8±2.44
8.5±1.22
8.1±1.78
8.63±0.76
1 (16.6)
1 (16.6)
1 (16.6)
2 (20)
3 (30)
3 (30)
-
-
1 (16.6)
1 (16.6)
1 (16.6)
4 (13.3)
5 (16.6)
5 (16.6)
-
Cerovac et al. Pregnancy and cancer
Table 3. Types of cancer/stage, treatment and time span from treatment to delivery
Type/stage of cancers
Total
(No, %)
Type of surgery
(No of women)
Chemotherapy (YES/NO)
(No of women)
Radiotherapy
(YES/NO)
(No of women)
Time
span from
treatment to
delivery
Genital
6 (20)
Ovarian cancer FIGO Ia
(Cystadenocarcinoma serosum)
1 (3.3)
Unilateral
adnexectomy (1)
NO
NO
24 months
Ovarian cancer FIGO IIIc
(Cystadenocarcinoma serosum)
2 (6.6)
Unilateral
adnexectomy,
Omentectomy (2)
6 cycles (taxol/carboplatina) (2)
NO
18 and 24
months
Embryonic ovarian cancer FIGO IIIc
(Ca embrionale ovarii)
1 (3.3)
Unilateral
adnexectomy,
Omentectomy
6 cycles (bleomycin, etoposid,
cysplatina)
NO
8 years
Breast cancer
- pT1bN0M0 (1)
- pT2bN1M0 (1)
(Carcinoma ductale invasivum)
2 (6.6)
Mastectomy (2)
6 cycles+hormonotherapy (letrosol,
tamoxifen) +imunotherapy (trastuzumab) (2)
1
24 months and
11 years
Extragenital
24 (80)
Cerebelar
(Astrocytoma anaplasticum)
1 (3.3)
Craniotomy and
tumour ablation
6 cycles chemotherapy
NO
8 years
Lateral ventricle
(High grade ependimoma)
1 (3.3)
Tumorectomy,
Ventriculocysternostomy, Ventriculoperitoneostomy
6 cycles chemotherapy
NO
5 years
Hepatic angiosarcoma
1 (3.3) Tumour extirpation
Amputation of
extremity
Osteosarcoma of the humerus
1 (3.3)
Abdominal ganglioneuroblastoma
1 (3.3) Tumour extirpation
Excision of the
1 (3.3)
tumour
Excision of the
1 (3.3)
tumour, lymph
node extirpation
Malignant melanoma pT1N0M0
Malignant melanoma pT2N1M0
Epipharingeal cancer pT1N0M0
(Carcinoma planocellulare)
6 cycles chemotherapy
NO
13 years
neoadjuvant and adjuvant
chemotherapy
NO
15 years
6 cycles
NO
13 years
NO
NO
12 months
4 cycle (dacarbazine)
YES
4 years
6 cycles (docetaxel, cisplatin, florouracil)
YES
5 years
24 months
3 – 8 years
1 (3.3)
NO
Thyroid gland (Carcinoma papillare
invasivum glandulae thyroideae)
1 (3.3)
Thyreoidectomy
(1)
NO
Radioactive iodine
treatment (1)
Thyroid gland (Carcinoma papillare
invasivum glandulae thyroideae)
pT1bN0M0 (5)
5 (16.6)
Thyreoidectomy
(5)
NO
Radioactive iodine
treatment (5)
Lymphoma Hodgkin IIA/B stage (Nodular sclerosis) (6)
8 (26.6)
IIIB stage (2)
NO
Multiple myeloma
NO
6 cycles
NO
3 years
NO
Before pregnancy: AD
(adriamycin+dexamethason) 3+7
protocol for induction and reinduction.
In pregnancy: cytosar
NO
24 months
Acute myeloid leukaemia M4 (FAB)
1 (3.3)
1 (3.3)
ber 2019) two (6.66%) women died. Their deaths
were caused by acute myeloid leukaemia M4
(two months after delivery) and ovarian cancer
FIGO IIIC, respectively (17 months after delivery) (Table 3).
DISCUSSION
In a systematic review by Gerstl et al. (6) the
women’s mean age at the time they were diagnosed with genital cancer, as well as the time of delivery was 30.5 and 30.3, respectively, which is
ABVD regimen (adriamycin+bleomyci Radiotherapy of the
n+Vinblastine+dacarbazine) (7)
neck and mediasti- 3 – 10 years
ABVD+BEA COPP regimen 4 cycle (1)
num (8)
higher than 21 and 27, respectively found in our
study. Approximately 12% of ovarian cancers
occurred under the age of 44 (6). Gerstl et al. reported that most women with ovarian cancer had
grade 1- stage IA, and underwent fertility-sparing
treatment including unilateral oophorectomy with
adjuvant chemotherapy, similar to our study (6).
In our study we have found four women with
ovarian cancer (three were with epithelial ovarian
cancers). According to the stage of ovarian cancer
one women was in stage FIGO IA, two in stage
461
Medicinski Glasnik, Volume 17, Number 2, August 2020
FIGO IIIC, and one with embryonic ovarian cancer in stage FIGO IIIC, and all had been treated
with unilateral adnexectomy and chemotherapy,
and gave birth to healthy newborns. Kashima et al.
(12) reported among 18 women who underwent
fertility sparing surgery with epithelial ovarian
cancer FIGO stage IC, seven singleton pregnancies for five women, compared to our results, four
singleton pregnancies in four women; they suggest
that fertility sparing surgery for ovarian cancer is a
valid treatment option for women of reproductive
age who strongly desire to conceive (12). Gerstl
et al. (6) reported 15% of miscarriages and 10%
of preterm birth rates, which is lower than in our
study, 16.6% and 16.6%, respectively.
In a systematic review and meta-analysis conducted by Gerstl et al. (7) the most commonly reported haematological diagnoses were Hodgkin
or non-Hodgkin lymphoma (40%), chronic myeloid leukaemia (21%), acute myeloid leukaemia
(15%), and acute lymphoblastic leukaemia (7%).
In our study we have found 33.3% of haematological diagnoses out of all cancers: Hodgkin
lymphoma 26.6%, multiple myeloma 3.3%, and
acute myeloid leukaemia 3.3%, which had been
treated with chemotherapy and radiotherapy.
De Sanctis et al. reported that the median time
from diagnosis to delivery was nine years, compared to 5.7 years in our study (13). The female/
male ratio in the Italian study was 51% / 49%
(10), which is different from our finding, 30%/
70%. The median birth weight found in the Italian study was similar to our data (3220 vs. 3144)
(13). De Sanctis et al. reported 12% of miscarriages, 7% of premature births, 2% of low birth
weight infants in women treated for Hodgkin
lymphoma, which is lower in comparison to our
results (13). In the study by De Sanctis et al. two
cases of congenital malformations were recorded
and no cases of stillbirths, while in our study no
cases of congenital malformations or stillbirths
were found (13). In our study 80% of women
with haematological cancer underwent radiotherapy (neck and mediastinum) and all women had
chemotherapy before pregnancy, which is higher
compared to the study by De Sanctis et al. (91%
and 66%, respectively) (13). A Serbian study (4)
reported good maternal and neonatal outcome
in women with acute myeloid leukaemia M4, in
contrast to our study.
462
Two studies (14,15) reported that the mean age
during the pregnancy and at delivery for thyroid
cancer women was 29.9 and 29.7 years, respectively, which means younger women compared
to our data (32.5). The same studies (14,15) reported that the duration between the diagnosis of
thyroid cancer and the beginning of pregnancy
was 40.5 and 60.9 months, respectively, in comparison with 51.6 months in our study. In the two
studies the median age of thyroid cancer diagnosis was 36 and 24.7 years, comparing to 28.1 in
our study (14,16). Hirsch et al. reported 47.6%
and 17.5% of women in T1 and T2 stage of the
disease, respectively, whereas in our study 83.3%
and 16.6% of women were in T1 and T2 stage of
the disease, respectively (14). In our study all patients underwent thyroidectomy and subsequent
radioactive iodine treatment (RAI) compared to
93.6% and 92%, respectively, in an Israeli study
(14). No women in our study had thyroid cancer
progression/recurrence during pregnancy, compared to 9.5% in the Israeli study (14). In a systematic review by Sawka et al. (8) it was found that
RAI treatment for thyroid carcinoma was not generally associated with an increase of long-term
risk of infertility, miscarriage, stillbirths, or congenital defects, which was the same for women
with thyroid carcinoma not treated with RAI; it
correlates with our results. Blackborn et al. (16)
reported complications connected with increased
risks for haemorrhage and diabetes/or abnormal
glucose tolerance during pregnancy, childbirth,
and the puerperium in thyroid cancer survivors.
We did not record these complications. Our study confirms that pregnancy does not have an impact on the recurrence of the disease in women
who survived thyroid cancer without evidence of
disease’s persistence before the conception.
A Turkish study (1) reported 68 pregnant women
who survived cancer, where the most frequently
encountered cancer types were thyroid (26.4%),
haematological (22.1%), genital (19.1%), and breast cancer (13.2%), which slightly differs from our
results (20%, 33.3%, 13.3% and 6.6%, respectively). The mean maternal age (31.7 vs. 29.4),
birth weight (3030 vs. 3202) and gestational age
(37.5 vs. 38.1) in Davutoğlu et al. study were very
similar to our findings (1); the prevalence of nulliparity (63.3%), miscarriages (13.3% vs. 2.9%),
preterm birth (10% vs. 8.8%), intrauterine growth
Cerovac et al. Pregnancy and cancer
restriction (IUGR) (8.8% vs. 5.8%) and gestational
hypertension / preeclampsia (8.8% vs. 2.9%) was
higher in our study, respectively. The most probable reason for this difference is that Davutoğlu et
al. excluded women with other coexisting medical
conditions and any sequelae associated with chemotherapy and radiotherapy from the analysis. A
Georgian study reported higher incidence of preterm delivery in breast cancer and leukaemia survivors in contrast to survivors of Hodgkin lymphoma, melanoma, and thyroid cancer (17). We
reported a high incidence of Caesarean section (60
%), which correlates with Davutoglu et al. (66.6%)
and Hartnett et al. studies (1,17). The high number
of women with miscarriages, IUGR and Caesarean
section in our study is probably a result of numerous comorbidities in pregnancies, earlier surgeries,
chemotherapy /radiotherapy /radioactive iodine
treatment, and older age of pregnant women. The
preterm rupture of membranes was found in 46.6%
of term gestations, mostly in haematological and
thyroid cancers (60% and 66.6%, respectively).
This is high frequency when compared to healthy
adolescent and adult pregnancies (39.44% and
21.33%), probably because of comorbidities and
consequences of cancer treatment (18).
The prevalence of admission to neonatal intensive care unit (NICU) in our study was higher than
in the Turkish study (16.6% vs. 8.8%), mostly
due to prematurity (1). There were no early neonatal deaths or congenital anomalies detected
in the newborns in both studies, but the Turkish
study reported one stillbirth (1). Miscarriage,
preterm birth and IUGR are common findings
among the offspring of female childhood cancer
survivors who received chemotherapy and abdominal, pelvic or total body irradiation (9,10,15).
Women intending to become pregnant after surviving cancer should be strongly supported, their pregnancy and delivery should be monitored
closely and in a multidisciplinary manner. The
influence of pregnancy on the course of cancer
and the risk of relapse has to be discussed individually with the patient, depending on the tumour
type and its stage (1).
Davutoglu et al. (1) reported four (out of 31) maternal deaths due to the advanced stage of breast and gastrointestinal cancers, which is higher
comparing to our finding, e.g. two maternal deaths (out of 30); both deaths in our study were
due to late diagnosis and advanced-stage cancers,
and both babies survived. The main objective in
such advanced cancers with poor maternal prognosis is to prolong the delivery to avoid extreme
prematurity (1,19).
Oncologists should offer oncofertility counselling and fertility preservation in women before
the start of cancer treatment (6,11,19,20). Women with cancer are generally advised to delay
pregnancy for up to 2 years following the cancer
treatment in order to identify possible relapse,
and because of the time needed for the oocyte to
recover from the damage caused by chemotherapy and radiotherapy (5,11,19,20). Women
who successfully conceive subsequently to the
treatment should be monitored throughout their
pregnancies by the treating gynaecological oncologist, foetal medicine and obstetrics and reproductive specialist in order to reduce potential
pregnancy and birth complications (6,11,19,20).
There are several limitations that should be addressed. Firstly, we describe women presented with
a combination of different cancers and treatments
without specifying which treatment resulted in a
specific reproductive outcome. Furthermore, there were inconsistencies and underreporting in
some patients in a dosage of chemo- and radiotherapy, and study population was small. Despite the limitations associated with this study, we
reported several interesting findings.
In conclusion, although in small sample, our data
demonstrate a favourable obstetric and neonatal
outcome for women who have survived cancer.
The women considering pregnancy after cancer
treatment should not be necessarily afraid, but
should be counselled carefully about perinatal risks and risks of recurrence. Prenatal care should
be tailored to the specific cancer and risks, and
appropriate support should be offered by the obstetrician and oncologist guiding that pregnancy.
FUNNDING
No specific funding was received for this study.
TRANSPARENCY DECLARATION
Conflict of interest: None to declare.
463
Medicinski Glasnik, Volume 17, Number 2, August 2020
REFERENCES
Alıcı Davutoğlu E, Madazlı R, Yılmaz N, Ozel A,
Uludag S, Sozen I. Pregnancy in cancer patients and
survivors; experience of a university hospital in Turkey. J Obstet Gynaecol 2017; 37:1015-9.
2. Clark H, Kurinczuk JJ, Lee AJ, Bhattacharya S. Obstetric outcomes in cancer survivors. Obstet Gynecol. 2007; 110:849-54.
3. Landa A, Kuller J, Rhee E. Perinatal considerations
in women with previous diagnosis of cancer. Obstet
Gynecol Surv 2015; 70:765-72.
4. Jeremic K, Stefanovic A, Dotlic J, Kadija S, Kontic
O, Gojnic M, Jeremic J, Kesic V. Cancer during pregnancy – clinical characteristics, treatment outcomes and prognosis for mothers and infants. J Perinat
Med 2018; 46:35-45.
5. Stensheim H, Cvancarova M, Møller B, Fosså SD.
Pregnancy after adolescent and adult cancer: a population-based matched cohort study. Int J Cancer
2011; 129:1225-36.
6. Gerstl B, Sullivan E, Vallejo M, Koch J, Johnson M,
Wand H, Webber K, Ives A, Anazodo A. Reproductive outcomes following treatment for a gynecological
cancer diagnosis: a systematic review. J Cancer Surviv 2019; 13:269-81.
7. Gerstl B, Sullivan E, Koch J, Wand H, Ives A,
Mitchell R, Hamad N, Anazodo A. Reproductive
outcomes following a stem cell transplant for a haematological malignancy in female cancer survivors:
a systematic review and meta-analysis. Support Care
Cancer 2019; 27:4451-60.
8. Sawka AM, Lakra DC, Lea J, Alshehri B, Tsang RW,
Brierley JD, Straus S, Thabane L, Gafni A, Ezzat S,
George SR, Goldstein DP. A systematic review examining the effects of therapeutic radioactive iodine
on ovarian function and future pregnancy in female thyroid cancer survivors. Clin Endocrinol (Oxf)
2008; 69:479-90.
9. Signorello LB, Cohen SS, Bosetti C, Stovall M, Kasper CE, Weathers RE, Whitton JA, Green DM, Donaldson SS, Mertens AC, Robison LL, Boice JD Jr.
Female survivors of childhood cancer: preterm birth
and low birth weight among their children. J Natl
Cancer Inst. 2006; 98:1453-61.
10. van der Kooi ALF, Kelsey TW , van den HeuvelEibrink MM , Laven JSE , Wallace WHB, Anderson
RA. Perinatal complications in female survivors of
cancer: a systematic review and meta-analysis. Eur J
Cancer. 2019; 111:126-37.
1.
464
11. Cerovac A, Ljuca D, Nevacinovic E, Tulumovic A,
Iljazovic E. Giving birth after fertility sparing treatment of embrional carcinoma Figo III C: case report and literature review. Med Arch 2018; 72:371-3.
12. Kashima K, Yahata T, Fujita K, Tanaka K. Outcomes of fertility sparing Surgery for women of reproductive age with FIGO stage IC epithelial ovarian
cancer. Int J Gynaecol Obstet 2013; 121:53-5.
13. De Sanctis V, Filippone FR, Alfò M, Muni R, Cavalieri E, Pulsoni A, Annechini G, Valeriani M, Osti
MF, Minniti G, Enrici RM. Impact of different treatment approaches on pregnancy outcomes in 99
women treated for Hodgkin lymphoma. Int J Radiat
Oncol Biol Phys 2012; 84:755-61.
14. Hirsch D, Levy S, Tsvetov G, Weinstein R, Lifshitz
A, Singer J, Shraga-Slutzky I, Grozinski-Glasberg
S, Shimon I, Benbassat C. Impact of pregnancy on
outcome and prognosis of survivors of papillary
thyroid cancer. Thyroid 2010; 20:1179-85.
15. Budak A, Gulhan I, Aldemir OS, Ileri A, Tekin E,
Ozeren M. Lack of influence of pregnancy on the
prognosis of survivors of thyroid cancer. Asian Pac J
Cancer Prev 2013; 14:6941-3.
16. Blackburn BE, Ganz PA, Rowe K, Snyder J, Wan Y,
Deshmukh V, Newman M, Fraser A, Smith K, Herget K, Kim J, Kirchhoff AC, Porucznik C, Hanson H,
Abraham D, Monroe M, Hashibe M. Reproductive
and gynecological complication risks among thyroid
cancer survivors. J Cancer Surviv 2018; 12:702-11.
17. Hartnett KP, Ward KC, Kramer MR, Lash TL, Mertens AC, Spencer JB, Fothergill A, Howards PP .The
risk of preterm birth and growth restriction in pregnancy after cancer. Int J Cancer 2017; 141:2187-96.
18. Marković S, Bogdanović G, Cerovac A. Premature and preterm premature rupture of membranes in
adolescent compared to adult pregnancy. Med Glas
(Zenica) 2020; 17:136-40.
19. Peccatori FA , Azim HA Jr, Orecchia R, Hoekstra
HJ, Pavlidis N, Kesic V, Pentheroudakis G; ESMO
Guidelines Working Group. Cancer, pregnancy and
fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;
24:vi160-70.
20. Barton SE , Najita JS, Ginsburg ES, Leisenring WM,
Stovall M, Weathers RE, Sklar CA, Robison LL,
Diller L. Infertility, infertility treatment, and achievement of pregnancy in female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol 2013; 14:873-81.